MET and neoplasm: In particular, the combination treatment of TAK-701 and gefitinib markedly reduces tumor growth in HCC827-HGF cell xenografts, a human NSCLC cell line with an activating EGFR mutation and HGF overexpression; this treatment also inhibited phosphorylation of c-MET, EGFR, ERK, and Akt [195].